Comorbid Conditions of Attention deficit / hyperactivity disorder

akronüüm: CoCA
algus: 2016-01-01
lõpp: 2020-12-31
 
programm: H2020 - Horisont 2020
alaprogramm: HEALTH - Tervishoid, demograafilised muutused ja heaolu
instrument: RIA
projektikonkurss: H2020-PHC-2015-two-stage
projekti number: 667302
kestus kuudes: 60
partnerite arv: 17
 
lühikokkuvõte: Understanding mechanisms underlying comorbid disorders poses a challenge for developing precision medicine tools. Psychiatric disorders are highly comorbid, and are among the last areas of medicine, where classification is driven by phenomenology rather than pathophysiology. We will study comorbidity between the most frequent psychiatric conditions, ADHD, mood/anxiety, and substance use disorders, and a highly prevalent somatic disease, obesity. ADHD, a childhood-onset disorder, forms the entry into a lifelong negative trajectory characterized by these comorbidities. Common mechanisms underlying this course are unknown, despite their relevance for early detection, prevention, and treatment. Our interdisciplinary team of experts will integrate epidemiologic/genetic approaches with experimental designs to address those issues. We will determine disease burden of comorbidity, calculate its socioeconomic impact, and reveal risk factors. We will study biological pathways of comorbidity and derive biomarkers, prioritizing two candidate mechanisms (circadian rhythm and dopaminergic neurotransmission), but also leveraging large existing data sets to identify new ones. A pilot clinical trial to study non-pharmacologic, dopamine-based and chronobiological treatments will be performed, employing innovative mHealth to monitor and support patients’ daily life. Integration of findings will lead to prediction algorithms enhancing early diagnosis and prevention of comorbidity. Finally, we will screen to repurpose existing pharmacological compounds. Integrating complementary approaches based on large-scale, existing data and innovative data collection, we maximize value for money in this project, leading to insight into the mechanisms underlying this comorbidity triad with its huge burden for healthcare, economy, and society. This will facilitate early detection and non-invasive, scalable, and low-cost treatment, creating opportunities for substantial and immediate societal impact.
partneri jrk nr ja roll partneri nimi riik kontaktisik koduleht
1 koordinaator JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN DE Andreas REIF http://www.uni-frankfurt.de
2 partner STICHTING KATHOLIEKE UNIVERSITEIT NL http://www.ru.nl
3 partner ACADEMISCH ZIEKENHUIS GRONINGEN NL http://www.umcg.nl
4 partner KAROLINSKA INSTITUTET SE http://www.ki.se
5 partner UNIVERSITAT DE BARCELONA ES http://www.ub.edu
6 partner FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES http://www.vhir.org
7 partner UNIVERSITATSMEDIZIN ROSTOCK DE http://www.med.uni-rostock.de
8 partner KING'S COLLEGE LONDON UK http://www.kcl.ac.uk
9 partner UNIVERSITAETSKLINIKUM HEIDELBERG DE
10 partner Tartu Ülikool EE http://www.ut.ee
11 partner KARLSRUHER INSTITUT FUER TECHNOLOGIE DE http://www.kit.edu
12 partner UNIVERSIDAD DE GRANADA ES http://www.ugr.es
13 partner UNIVERSITETET I BERGEN NO http://www.uib.no
14 partner THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK US http://www.rfsuny.org
15 partner AARHUS UNIVERSITET DK http://www.au.dk
16 partner HGC Gesundheitsconsult GmbH DE http://www.gesundheitsconsult.de
17 partner Concentris Research Management GmbH DE http://www.concentris.de